粤万年青(301111.SZ)公告称，持股5%以上股东合和投资控股（广州）合伙企业（有限合伙）因自身资 金需求，计划通过集中竞价交易、大宗交易方式减持公司股份不超过480万股，即不超过公司总股本的 3.00%。减持期间为公告披露之日起15个交易日后的3个月内。 ...

格隆汇11月11日｜粤万年青(301111.SZ)公告称，持股5%以上股东合和投资控股（广州）合伙企业（有 限合伙）因自身资金需求，计划通过集中竞价交易、大宗交易方式减持公司股份不超过480万股，即不 超过公司总股本的3.00%。减持期间为公告披露之日起15个交易日后的3个月内。 ...

持有广东万年青制药股份有限公司（以下简称"公司"）股份 11,200,000 股（占公司总股本的 7.00%）的股东合和投资控股（广州）合伙企业（有限合伙） （以下简称"合和投资"）计划在本公告披露之日起 15 个交易日后的 3 个月内 以集中竞价交易、大宗交易方式合计减持公司股份不超过 4,800,000 股，即减持 比例不超过公司总股本的 3.00%。 公司于近日收到公司股东合和投资出具的《股东减持计划告知函》，现将有 关情况公告如下： 证券代码：301111 证券简称：粤万年青 公告编号：2025-056 广东万年青制药股份有限公司 关于持股5%以上股东股份减持计划的预披露公告 股东合和投资控股（广州）合伙企业（有限合伙）保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 一、股东的基本情况 1、股东名称：合和投资控股（广州）合伙企业（有限合伙） 2、股东持股情况：截至本公告披露日，合和投资持有公司股份的总数量为 11,200,000 股，占公司总股本比例为 7.00%。 二、本次减持计划的 ...

证券代码：301111 证券简称：粤万年青 公告编号：2025-055 广东万年青制药股份有限公司 关于控股股东、实际控制人之一致行动人股份减持计划的预 披露公告 本公司控股股东、实际控制人之一致行动人汕头市银康企业管理咨询合伙 企业（有限合伙）保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 广东万年青制药股份有限公司（以下简称"公司"）控股股东、实际控制人 之一致行动人汕头市银康企业管理咨询合伙企业（有限合伙）（以下简称"银康 管理"）持有公司股份 1,061,520 股（占公司总股本的 0.66%），计划在本公告 披露之日起 15 个交易日后的 3 个月内以集中竞价交易方式合计减持公司股份不 超过 1,061,520 股，即减持比例不超过公司总股本的 0.66%。 公司于近日收到公司股东银康管理出具的《股东减持计划告知函》，现将有 关情况公告如下： 一、股东的基本情况 1、股东名称：汕头市银康企业管理咨询合伙企业（有限合伙） 2、股东持股情况：截至本公告披露日，银康管理持有公司股份的总数量 ...

Group 1 - The core viewpoint of the news is that Guangdong Wannianqing Pharmaceutical Co., Ltd. is experiencing a decline in stock performance and financial metrics, with significant changes in financing activities and shareholder structure [1][2]. Group 2 - On November 6, Guangdong Wannianqing's stock price fell by 1.61%, with a trading volume of 30.78 million yuan. The financing buy-in amount was 2.14 million yuan, while the financing repayment was 4.38 million yuan, resulting in a net financing buy of -2.23 million yuan [1]. - As of November 6, the total balance of margin trading for Guangdong Wannianqing was 51.48 million yuan, which accounts for 1.88% of its circulating market value, indicating a low financing balance compared to the past year [1]. - The company had no short-selling activities on November 6, with a short-selling balance of 0.00 yuan, which is at a high level compared to the past year [1]. - As of September 30, the number of shareholders for Guangdong Wannianqing was 11,400, a decrease of 7.18% from the previous period, while the average circulating shares per person increased by 7.74% to 13,994 shares [2]. - For the period from January to September 2025, Guangdong Wannianqing reported an operating income of 228 million yuan, a slight decrease of 0.14% year-on-year, and a net profit attributable to shareholders of -8.13 million yuan, a significant decrease of 157.65% year-on-year [2]. - Since its A-share listing, Guangdong Wannianqing has distributed a total of 65.6 million yuan in dividends, with 40 million yuan distributed over the past three years [2].

Core Viewpoint - Guangdong Wannianqing Pharmaceutical Co., Ltd. is experiencing a decline in revenue and net profit, while its financing activities indicate a low level of market engagement and high short-selling potential. Group 1: Financial Performance - As of September 30, 2023, the company reported a revenue of 228 million yuan, a year-on-year decrease of 0.14% [2] - The net profit attributable to the parent company was -8.13 million yuan, representing a year-on-year decrease of 157.65% [2] Group 2: Shareholder and Market Activity - The number of shareholders decreased to 11,400, a reduction of 7.18% compared to the previous period [2] - The average number of circulating shares per shareholder increased to 13,994 shares, an increase of 7.74% [2] Group 3: Financing and Margin Trading - On November 5, 2023, the company had a financing buy-in amount of 3.50 million yuan, with a net financing buy of 944,100 yuan [1] - The total financing and margin trading balance was 53.72 million yuan, accounting for 1.93% of the circulating market value, which is below the 50th percentile level over the past year [1] - The company had no short-selling activity on November 5, 2023, with a short-selling balance of 0 yuan, indicating a high level of short-selling potential compared to the 90th percentile level over the past year [1] Group 4: Dividend Distribution - Since its A-share listing, the company has distributed a total of 65.60 million yuan in dividends, with 40 million yuan distributed over the past three years [3]

Group 1 - The core point of the article is that Guangdong Wannianqing Pharmaceutical Co., Ltd. announced the transfer of equity stakes in Shantou Beikang Enze Health Management Co., Ltd. to Huayin Group and Hangzhou Beikang Health Technology Group, resulting in a significant change in its ownership structure [1] - Guangdong Wannianqing's wholly-owned subsidiary, Wannianqing International Medical Management (Shantou) Group Co., Ltd., will transfer 60% of its stake in Beikang Enze for 12 million yuan and 10% for 2 million yuan, leading to a complete divestment from Beikang Enze [1] - Following the transaction, the ownership percentage of Beikang Enze held by Wannianqing International will decrease from 70% to 0%, and Beikang Enze will no longer be included in the company's consolidated financial statements [1] Group 2 - As of the report date, Guangdong Wannianqing has a market capitalization of 2.7 billion yuan [2] - For the fiscal year 2024, the revenue composition of Guangdong Wannianqing is projected to be 97.36% from pharmaceuticals, 1.53% from other sources, 0.57% from medical services and health management, and 0.53% from medicinal slices [1]

Core Viewpoint - The company reported a decline in revenue and a net loss for the first three quarters of 2025 compared to the previous year [1] Financial Performance - For the first three quarters of 2025, the company achieved an operating income of 228 million yuan, a year-on-year decrease of 0.14% [1] - The net profit attributable to shareholders of the listed company was a loss of 8.1295 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of 13.3186 million yuan [1] - The basic earnings per share were reported at -0.0508 yuan [1]

广东万年青制药股份有限公司 一、交易概述 关于转让控股子公司部分股权的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、广东万年青制药股份有限公司（以下简称"公司"）与广东合一云康医 药有限公司（以下简称"合一云康"）签署《股权转让协议》，拟将公司持有的 控股子公司海南万秘堂医药有限公司（以下简称"海南万秘堂"）51%的股权转 让给合一云康，转让价格为 3,373,543.10 元。交易完成后，公司不再持有海南 万秘堂股权，海南万秘堂不再纳入公司合并报表范围。公司将按照企业会计准则 的相关要求进行会计处理，预计将增加公司本期净利润，具体会计处理及影响数 以会计师年度审计确认后的结果为准。 2、本次股权转让事项不构成关联交易，也不构成《上市公司重大资产重组 管理办法》规定的重大资产重组。 证券代码：301111 证券简称：粤万年青 公告编号：2025-054 3、本次交易已经公司第三届董事会第九次会议审议通过，根据《深圳证券 交易所创业板股票上市规则》（以下简称"股票上市规则"）相关规定，本次交 易无需提交股东会审议。 1 合伙企业（有限合伙 ...

证券代码：301111 证券简称：粤万年青 公告编号：2025-053 广东万年青制药股份有限公司 关于全资子公司转让下属控股公司股权暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、广东万年青制药股份有限公司（以下简称"公司"）全资子公司万年青 国际医疗管理（汕头）集团有限公司（以下简称"国际医疗"）与汕头市华银集 团有限公司（以下简称"华银集团"）、杭州贝康健康科技集团有限公司（以下 简称"杭州贝康"）签署《股权转让协议》，拟将其持有的汕头贝康恩泽健康管 理有限公司（以下简称"贝康恩泽"）60%股权转让给华银集团，转让价格为 1,200 万元；将其持有的贝康恩泽 10%股权转让给杭州贝康，转让价格为 200 万元。交 易完成后，国际医疗持有贝康恩泽的股权比例由 70%变更为 0%，贝康恩泽不再纳 入公司合并报表范围。 2、本次交易股权转让价格系以国际医疗对贝康恩泽已实缴的注册资本 1,400 万元为定价依据，交易完成后预计将增加公司本期净利润，具体会计处理及影响 数以会计师年度审计确认后的结果为准。 3、鉴于交易对手方之一华 ...